Acelyrin, Inc.
5.30%
5,298,328
1962918
00445A100
Feb 17, 2025
Feb 20, 2025, 04:15 PM
Reporting Persons (7)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT, LLC | Other | 5.30% | 5,298,328 | 0 | 5,298,328 |
| KEVIN TANG | Individual | 5.30% | 5,298,328 | 0 | 5,298,328 |
| TANG CAPITAL PARTNERS, LP | Partnership | 3.00% | 2,979,781 | 0 | 2,979,781 |
| TANG CAPITAL PARTNERS INTERNATIONAL, LP | Partnership | 2.30% | 2,318,547 | 0 | 2,318,547 |
| TANG CAPITAL PARTNERS III, INC | CO | 0.00% | 0 | 0 | 0 |
| TANG CAPITAL PARTNERS IV, INC | CO | 0.00% | 0 | 0 | 0 |
| CONCENTRA BIOSCIENCES, LLC | Other | 0.00% | 0 | 0 | 0 |
Disclosure Items (7)
Common Stock, par value $0.00001 per share
Acelyrin, Inc.
4149 LIBERTY CANYON RD., AGOURA HILLS, CA, 91301
This Statement is filed by TCM, a Delaware limited liability company that is the general partner of TCP and TCPI; Kevin Tang, a United States citizen; TCP, a Delaware limited partnership engaged in capital management; TCPI, a Delaware limited partnership engaged in capital management; Tang Capital Partners III, Inc., a Nevada corporation that is indirectly wholly owned by TCP ("TCP III"); Tang Capital Partners IV, Inc., a Nevada corporation that is indirectly wholly owned by TCP ("TCP IV"); and Concentra Biosciences, LLC, a Delaware limited liability company controlled by TCP ("Concentra" and, collectively with TCM, Kevin Tang, TCP, TCPI, TCP III and TCP IV, the "Reporting Persons").
The address of TCM, Kevin Tang, TCP, TCPI and Concentra is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of TCP III and TCP IV is 5955 Edmond Street, Las Vegas, NV 89118.
Kevin Tang is the manager of TCM. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV. Kevin Tang is the Chief Executive Officer of Concentra.
During the past five years, none of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
See Item 2(a) above.
The Common Stock was acquired with approximately $10.9 million of working capital set aside by TCP and TCPI for the general purpose of investing. TCP and TCPI maintain commingled margin accounts with various financial institutions, which may extend margin credit to TCP and TCPI as and when required, to open or carry positions in the margin accounts, subject to applicable federal margin regulations, stock exchange rules and credit policies. In such instances, the positions held in the margin accounts are pledged as collateral security for the repayment of debit balances in the accounts. The margin accounts may from time to time have debit balances. Since multiple different securities are held in the margin accounts, it is not possible to determine the amounts, if any, of margin used to purchase the Common Stock reported herein.
The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. As of the date hereof the Reporting Persons beneficially own an aggregate of 5,298,328 shares of the Issuer's Common Stock, representing 5.3% of the outstanding shares.
See item 5(a) above.
Schedule A attached hereto as Exhibit 3 describes all transactions in the Issuer's Common Stock that were effected during the past 60 days by the Reporting Persons.
No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock beneficially owned by the Reporting Persons.
Not applicable
To the best of the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons or between the Reporting Persons and any person with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.
Exhibit 1: Joint Filing Agreement by and among the Reporting Persons. Exhibit 2: Acquisition Proposal, dated February 20, 2025, sent from Concentra to the Issuer. Exhibit 3: Schedule A: Transactions during the past 60 days.